Shots:

• The P-I trial (to be funded by The Michael J. Fox Foundation for Parkinson’s Research) aims at assessing the safety, tolerability & PK profile of IRL757 among healthy participants in two parts where 1st part administers single ascending doses & the 2nd part administers multiple ascending doses (MAD). Additionally, will document impact of concomitant food intake
• The drug has demonstrated the ability to prevent disruptions in the nerve signaling between the cerebral cortex and deeper brain parts across various preclinical models of cognitive function, addressing apathy
• Furthermore, the company plans to conclude the trial at the end of 2024 with the topline data anticipated in Q1’25

Ref: IRLAB Therapeutics | Image:IRLAB Therapeutics

Related News:- Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com